The proprietary technology platform utilizes a new benzene polycarboxylic acids compound, which is prepared by alkaline oxidation of hydrolyzed lignin, used as part of a composite substance, where the composite substance is prepared by complexing the new benzene polycarboxylic acid compounds with a metal cation. The water-soluble polymer of benzene polycarboxylic acids exhibits its own biological effect.

Chemical properties of the new water-soluble polymer compound of benzene polycarboxylic acids make it possible to obtain a broad range of highly stable complexes, as well as pharmaceutical, nutraceutical and cosmetic compositions for parenteral, enteral and topical administration to human beings and animals.

The patents of Meabco A/S relates to

Composition

  • A new benzene polycarboxylic acids compound, which is prepared by alkaline oxidation of hydrolyzed lignin.
  • The use of the new benzene polycarboxylic acids compound as part of a composite substance, where the composite substance is prepared by complexing or encapsulating the new benzene polycarboxylic acid compounds with a metal cation.

Production process

  • A method for preparing the new benzene polycarboxylic acids compound by alkaline oxidation of hydrolyzed lignin,

Usage and Application

  • For its use in cosmetic, nutraceutical and pharmaceutical compositions.
  • preferred routes of administration.

Patent family claims priority of Danish patent application PA 2012 70159 and US provisional application 61/618.037 both filed 30 March 2012. The claims of the applications of the patent family are directed to:

  • The proprietary technology platform;
  • A process for preparing The proprietary technology platform from a lignin containing starting material;
  • BP-C1 (defined as a composite of a water-soluble polymer of benzene polycarboxylic acid);
  • A process for preparing BP-C1 from a lignin containing starting material;
  • Drug comprising BP-C1;
  • BP-C2 (defined as a composite of a water-soluble polymer of benzene polycarboxylic acids and molybdenum);
  • A process for preparing BP-C2 from a lignin containing starting material;
  • Drug comprising BP-C2;
  • A method for treatment of a disease (e.g. cancer) with BP-C1 or BP-C2;
  • A method for reducing side effects of radiation therapy or chemotherapy with BP-C1 or BP-C2;
  • Combination with other cancer drugs.

The international patent authority has acknowledged novelty, inventive step and industrial applicability of all of these types of claims.

Divisional applications

In addition to the claimed subject matter the patent applications of this patent family also describe pharmaceutical compositions comprising a combination of BP-C1 and BP-C2 with various specific conventional anti-cancer agents. Accordingly, divisional applications may be filed, which are specifically directed to such aspects.

Main aspects of Meabco’s products are covered by patents until 2033.